Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...
United Kingdom, London, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Introspective Market Research is pleased to announce the ...
The US Food and Drug Administration (FDA) approved expanding the prescribing information for Japanese drugmaker Astellas ...
Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...
Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...
IZERVAY dosing approved beyond 12 monthsTOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Ok ...
HeartcoR Solutions, a leading ECG core lab that conducts cardiac safety studies for the pharmaceutical, medical device, and ...
Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.
Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results